Regulatory & Legal

Australian biotech Gelteq has a gel that makes bitter medicine taste good to dogs. It's more than a pet owner's dream—it's a strategic move in a $47B market.

New data reveals a shocking AI divide. Mars Petcare brands dominate AI search, while 80% of independent vets have become digitally invisible to pet owners.

For decades, patients with a rare autoimmune anemia faced a cycle of steroids and relapse. New data on a targeted therapy may finally offer a durable solution.

A new FDA-designated device aims to filter a deadly protein from the blood of sepsis patients. Can this novel approach finally conquer a global health crisis?

The abrupt resignation of a top executive at ASA Gold and Precious Metals raises serious questions about internal controls, transparency, and corporate accountability.

A new heavy-lift drone can autonomously airdrop supplies into contested zones with precision, signaling a fundamental shift in military and humanitarian aid.

A bitter global patent war ends quietly. We dissect how the Amazon-InterDigital pact reveals the hidden costs of innovation and the new rules of tech engagement.

Paradisus La Perla's new WITT certification isn't just an award; it's a strategic move by Meliá to capture the booming $1.3T wellness travel market.

As John Anthony Vineyards uncorks a 20th-anniversary Cabernet, the celebration reveals a larger strategy: a quiet pivot from a boutique winery to a diverse beverage empire.

A century-old seal of trust meets a new-age disruptor. We deconstruct how HOTO's design philosophy and smart technology are redefining home cleaning.

A BMO survey reveals a stark new reality: financial stability is trumping romance, trapping some in marriage and turning partnership into a fiscal strategy.

Hyundai Bioscience offers a free drug for an untreatable Ebola strain. It's a bold humanitarian gesture, and a masterclass in strategic maneuvering.

Meta's API changes have advertisers seeing red, but a drop in reported conversions doesn't mean a drop in real-world results. Here's what it really means.

When a nation-state actor targeted Utah's water infrastructure, a Native American-owned firm didn't just survive. They built a fortress. Here's how.

Oxford Commercial Finance's milestone isn't just a number; it's a sign of a deep shift. As traditional banks step back, who is funding America's growth?

In a region hit hard by lung cancer, Tanner Health proves innovation isn't just for big cities, deploying a powerful AI to save lives in Georgia and Alabama.

A market set to triple, driven by gene-level therapies, promises a revolution for children with rare epilepsies. But can our systems deliver this hope?

Cytovance Biologics' new cell line service boasts top-tier yields. This strategic shift toward a 'one-stop-shop' model could redefine speed and cost in biopharma.

Following a controversial board purge, ousted Pangaea directors are threatening a shareholder revolt, raising critical questions about corporate oversight.

Organon's FDA nod for TOFIDENCE in critical care isn't just a clinical win. It's a calculated move to capture market share and challenge high-cost biologics.